X4 Pharmaceuticals, Inc.
XFOR
$4.10
$0.030.74%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 45.50% | -10.54% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 45.50% | -10.54% | |||
| Cost of Revenue | 3.70% | 7.67% | |||
| Gross Profit | 55.87% | -14.15% | |||
| SG&A Expenses | -9.82% | -14.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.59% | -13.58% | |||
| Operating Income | -5.71% | 13.81% | |||
| Income Before Tax | 19.84% | -16.11% | |||
| Income Tax Expenses | 100.00% | -181.08% | |||
| Earnings from Continuing Operations | 19.76% | -15.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.76% | -15.83% | |||
| EBIT | -5.71% | 13.81% | |||
| EBITDA | -5.76% | 13.49% | |||
| EPS Basic | 68.59% | 80.16% | |||
| Normalized Basic EPS | 62.14% | 83.37% | |||
| EPS Diluted | 68.58% | 80.13% | |||
| Normalized Diluted EPS | 62.14% | 83.37% | |||
| Average Basic Shares Outstanding | 155.49% | 483.74% | |||
| Average Diluted Shares Outstanding | 155.49% | 483.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||